Award
National Cancer Institute RFA-CA-22-028
Next generation T cell therapies for mutant KRAS solid tumors
Recipient
University of Pennsylvania
Award Amount
$2,238,704.00
Ceiling
$2,238,704.00
Awarded
September 19, 2025
Identifier
RFA-CA-22-028
Award for developing innovative T cell therapies targeting mutant KRAS in solid tumors, funded by NIH/NCI with a focus on gene editing and biomarker discovery.
Description
The project involves developing T cell therapies targeting mutant KRAS in solid tumors. The project includes multiple scientific and technological innovations, including gene editing and biomarker discovery. The project leverages NCI resources and the Immune Cell Network (ICN) Core at FNLCR. The project team includes investigators with expertise in immunology, immuno-oncology, cell therapy, and gene editing.